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Abstract
Cytochrome P450 3A4 (CYP3A4), the major form of P450 expressed in the adult human liver, is involved in the metabolism of about 50% of commonly prescribed drugs. Several genetic polymorphisms in CYP3A4 are known to affect its catalytic activity and to contribute in part to interindividual differences in the pharmacokinetics and pharmacodynamics of CYP3A4 substrate drugs. In this study, catalytic activities of the two alleles found in East Asians, CYP3A4*16 (T185S) and *18 (L293P), were assessed using seven substrates, midazolam, carbamazepine, atorvastatin, paclitaxel, docetaxel, irinotecan, and terfenadine.
The holoprotein levels of CYP3A4.16 and CYP3A4.18 were significantly higher and lower, respectively, than that of CYP3A4.1 when expressed in Sf21 insect cell microsomes together with human NADPH-P450 reductase. CYP3A4.16 exhibited considerably lowered (by 84-60%) intrinsic clearances (V max /K m ) for metabolism of midazolam, carbamazepine, atorvastatin, paclitaxel, and irinotecan as compared with CYP3A4.1 due to increased K m with or without decreased V max values, while no apparent decrease in intrinsic clearance was observed for docetaxel. On the other hand, K m values of CYP3A4.18 were comparable to those of CYP3A4.1 for all substrates except terfenadine; but V max values were lower for midazolam, paclitaxel, docetaxel, irinotecan, resulting in partially reduced intrinsic clearance values (by 34-52%). These results demonstrated that impacts of both alleles on CYP3A4 catalytic activities depend on the substrates used. Thus, to evaluate the influences of both alleles on the pharmacokinetics of CYP3A4-metabolized drugs and their drug-drug interactions, substrate drug-dependent characteristics should be considered for each drug.
Introduction
Cytochrome P450 3A4 (CYP3A4), the major form of P450 expressed in the adult human liver, is involved in the metabolism of about 50% of commonly prescribed drugs (Guengerich, 1999) . CYP3A4 is capable of oxidizing a wide range of structurally diverse drugs as well as endogenous compounds. For example, many anticancer drugs, such as docetaxel, paclitaxel, etoposide, tamoxifen, irinotecan, vinblastine, and cyclophosphamide, are known to be metabolized by CYP3A4.
The expression and catalytic activity of CYP3A are highly variable among individuals, and this variability is partially attributable to genetic factors (Ozdemir et al., 2000) . Several
CYP3A4 genetic polymorphisms are known to affect the metabolism of CYP3A4 substrate drugs (http://www.cypalleles.ki.se/cyp3a4.htm). In addition, CYP3A4 alleles were reported to exhibit large ethnic differences in their distribution. In Japanese, 4 alleles with amino acid alterations, *6 (D277EfsX8), *11 (T363M), *16 (T185S) and *18 (L293P), are found at frequencies of < 0.001, 0.002, 0.014 -0.05 and 0.013-0.028, respectively (Lamba et al., 2002; Yamamoto et al., 2003; Fukushima-Uesaka et al., 2004) . Of these alleles, *16 has also been detected in Korean (0.002 allele frequency) and Mexican populations (0.05), and *18 is commonly distributed among East Asians such as Chinese (0.008-0.01), Koreans (0.012-0.017) and Malaysians (0.021) (Wen et al., 2004; Hu et al., 2005; Lee et al., 2007; Ruzilawati et al., 2007; Kang et al., 2009 (Sai et al., 2008) .
In contrast to CYP3A4*16, CYP3A4*18 seems to be bidirectional in terms of its catalytic activity toward different substrates although different evaluation systems were used for each study. For example, the CYP3A4.18 protein exhibited increased activity for testosterone and chlorpyrifos (Dai et al., 2001 ), but not for nifedipine (Lee et al., 2005) in vitro. On the other hand, for the conventional probe drug midazolam, CYP3A4.18 showed decreased metabolism in vitro but not in vivo (Lee et al., 2007) . Kang et al. (2009) demonstrated that CYP3A4*18 is the gain-of-function allele for metabolism of several CYP3A4 substrates, including sex steroids like estrogens, leading to a relative sex-hormone deficiency, which may predispose older women to osteoporosis.
In this study, to evaluate the effects of CYP3A4*16 and CYP3A4*18 on the catalytic activity toward structurally diverse substrates, recombinant wild-type (CYP3A4.1) and variant CYP3A4 enzymes (CYP3A4.16 and CYP3A4.18) were expressed using baculovirus-insect cell systems. The seven substrates used in the investigation were midazolam (MDZ), carbamazepine (CBZ), atorvastatin (ATV), paclitaxel (PTX), docetaxel (DTX), irinotecan (IRN) and terfenadine (TFN) (supplemental data, Fig. S1 ).
This article has not been copyedited and formatted. The final version may differ from this version. 
Expression of recombinant wild-type and mutant CYP3A4 proteins
Insect cell microsomes coexpressing CYP3A4 (wild-type or variants) and NADPH P450 reductase (OR) were prepared according to the methods described previously (Maekawa et al., 2009 ). The cytochrome P450 content and OR activity in microsomes were measured (Omura and Sato, 1964; Phillips and Langdon, 1962) , and Western blotting of CYP3A4 and OR was performed as described previously (Maekawa et al., 2009 ).
Assay for CYP3A4 activity
To compare alterations in kinetic parameters among substrates, three batches of wild This article has not been copyedited and formatted. The final version may differ from this version. Catalytic activities for MDZ 1'-and 4-hydroxylations, CBZ 10, 11-epoxide formation were measured as described previously (Maekawa et al., 2009 ) with slight modifications.
For other substrates (ATV, PTX, DTX, IRN and TFN), the incubation conditions were similar to those used for MDZ and CBZ. For all substrates, CYP3A4s from insect microsomes and purified cytochrome b5 were mixed together (CYP3A4 : b5 = 1 : 4), and protein concentrations and the OR to P450 ratio in the CYP3A4 wild-type and variant reaction mixtures were adjusted to be equivalent by adding both control (uninfected) microsomes and microsomes expressing solely OR. MDZ (0.2-200 μM), CBZ (10-500 μM),
were added into aliquots of above mentioned enzyme preparations.
Reaction was started by adding NADPH generation system and terminated by adding appropriate stop solutions containing suitable internal standard for measurement of each metabolite. Samples were mixed well and then spun at 13,000 x g for 3-5 min.
Metabolite analyses for MDZ, CBZ, ATV and PTX were carried out on a tandem quadrupole mass spectrometer (Quattro Premier XE; Waters Micro-mass, Manchester, UK)
interfaced with an Acquity UPLC System (Waters, Milford, MA, USA) equipped with an Acquity BEH C18 column (1.7µm; 2.1 x 30 mm, Waters), kept at 50 °C. Two solutions (A:
10 mM ammonium acetate, B: 90% acetonitrile containing 10 mM ammonium acetate) were This article has not been copyedited and formatted. The final version may differ from this version. Kinetic parameters were calculated using the computer program designed for non-linear regression analysis (MULTI program, Yamaoka et al. 1986 ). Kinetic parameters for MDZ 4-hydroxylation, ATV 2-and 4-hydroxylation, PTX 3'-p-hydroxylation, IRN oxidation to NPC, and DTX t-butyl hydroxylation were determined by the hyperbolic Michaelis-Menten model (eq 1). The substrate inhibition model (eq 2) was used for MDZ 1'-hydroxylation, TFN C-hydroxylation and TFN N-demethylation, where K s is the substrate inhibition constant. In the case of the 10, 11-epoxidation of CBZ, kinetic parameters were determined by the modified two-site equation (V max1 = 0) (Korzekwa et al. 1998 ) (eq 3).
Kinetic data was determined as the mean ± SD for three microsomal preparations derived from separate baculovirus infections, and statistical analysis was conducted by 
Catalytic activities of wild-type and variant CYP3A4s
To characterize the substrate-dependent functional alterations of CYP3A4*16 and Our results were consistent with those by Miyazaki et al. (2008) significantly reduced metabolite/substrate AUC ratios, which are parameters for in vivo CYP3A4 activity (Nakajima et al., 2006; Sai et al., 2008 (Table 1 and supplemental data, Fig. S3 ), which has the lowest molecular weight among the 7 substrates (supplemental data, Fig.S1 ).
For the substrates MDZ, PTX, and IRN, it was reported that heterozygous CYP3A4*1/*18 did not affect their pharmacokinetics (Nakajima et al., 2006; Lee et al., 2007; Sai et al., 2008 By molecular modeling studies, Kang et al. (2009) 
demonstrated that the Leu293Pro
